Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103217 | 1.00 | PARP1 (0.46) | PARP1USP2SMN1; SMN2HSD17B10CHRM2 | |
| SCHEMBL102292 | 1.00 | PARP1 (0.46) | PARP1USP2SMN1; SMN2HSD17B10CHRM2 | |
| Potassium SCHEMBL30616188 | 0.98 | PARP1 (0.45) | PARP1USP2SMN1; SMN2HSD17B10CHRM2 | |
| Methane SCHEMBL28975622 | 0.98 | PARP1 (0.45) | PARP1USP2SMN1; SMN2HSD17B10CHRM2 | |
| Hydrochloric Acid SCHEMBL377440 | 0.98 | PARP1 (0.45) | PARP1USP2SMN1; SMN2HSD17B10CHRM2 | |
| Urea SCHEMBL4458708 | 0.95 | PARP1 (0.43) | PARP1USP2SMN1; SMN2HSD17B10DPP4 | |
| SCHEMBL25212939 | 0.90 | PARP1 (0.41) | PARP1USP2SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL25268281 | 0.90 | PARP1 (0.41) | PARP1USP2SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL25416105 | 0.90 | PARP1 (0.41) | PARP1USP2SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL22604987 | 0.88 | HPGD (0.41) | PARP1SMN1; SMN2HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105777658-A | Synthesis method of medicine intermediate 1-tert-butyloxycarboryl-2-methylpiperazine | 无锡乾浩生物医药有限公司 | 2016-07-20 | — | — | CN | claimed |
| WO-1990000551-A1 | PROCESS FOR THE PREPARATION OF QUINOLINE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 1990-01-25 | — | — | WO | claimed |
| EP-0350950-A1 | Process for the preparation of quinoline antibacterial compounds | ABBOTT LABORATORIES (US) | 1990-01-17 | — | — | EP | claimed |
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026086794-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2026-04-30 | — | — | WO | disclosed |
| EP-3565808-B1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260042770-A1 | NOVEL SULFONES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2026-02-12 | — | — | US | disclosed |
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2026-01-22 | — | — | US | disclosed |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4665331-A1 | ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-1997001275-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| EP-0727421-A1 | Agents for improving sleep | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-08-21 | — | — | EP | disclosed |
| WO-1995000497-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-01-05 | — | — | WO | disclosed |
| US-5026853-A | Sleep and cardiovascular disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-06-25 | — | — | US | disclosed |
| US-4968684-A | N-ARYL-PIPERAZINEALKANAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-11-06 | — | — | US | disclosed |
| WO-1990000551-A1 | PROCESS FOR THE PREPARATION OF QUINOLINE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 1990-01-25 | — | — | WO | disclosed |
| EP-0350950-A1 | Process for the preparation of quinoline antibacterial compounds | ABBOTT LABORATORIES (US) | 1990-01-17 | — | — | EP | disclosed |
| US-4880808-A | SEDATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-11-14 | — | — | US | disclosed |
| EP-0285219-A2 | Method of improving sleep | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042770-A1 | NOVEL SULFONES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | BDNF, CNR1, GFRA1 | PARP1 3888/4885USP2 2896/4885SMN1; SMN2 6/4885 |
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | PARP1 3042/4885USP2 3299/4885SMN1; SMN2 3529/4885 |
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | CNR1, CDR2, SMN1; SMN2 | PARP1 3692/4885USP2 2610/4885SMN1; SMN2 3/4885 |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP4A11, CYP11B1, CYP2D6 | PARP1 3576/4885USP2 4338/4885SMN1; SMN2 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.